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Serum antibodies to the capsular polysaccharide (CPS) ~ of Neisseria meningiti- 
dis,  as  well as  to other encapsulated bacterial  pathogens, confer immunity to 
invasive  diseases  caused  by  these  organisms  (1-6).  There  is  an  age-related 
development of meningococcus group  A  (GrA)  CPS  antibodies  (1,  2,  4-6). 
During infancy and childhood, when placentaily required antibodies have de- 
clined and adult levels have not yet developed, the attack rate of GrA meningitis 
is at its highest (1).  GrA diseases have a different epidemiological pattern than 
the other two major pathogenic groups of meningococci (B and C). GrA diseases 
occur annually with high frequency in central Africa (7-9). In other parts of the 
world, GrA diseases occur as epidemics lasting one or two years (9-11). Yet, in 
both endemic and epidemic situations, asymptomatic carriage of GrA organisms 
is low, ~3% (10,  12,  13).  In the United States, GrA organisms have been only 
rarely detected either in patients or in asymptomatic carriers during the past 30 
years (10,  14-17).  Despite the absence or low carriage rate of the homologous 
organism, most adults in all these countries have protective levels of GrA CPS 
antibodies (1,  2,  18).  It has been proposed (18-26) that an important antigenic 
stimulus for C PS antibodies, including those of GrA, is the asymptomatic carriage 
of crossreacting bacteria of the respiratory and of the gastrointestinal tract (18- 
26). To date, two strains of bacteria have been reported to crossreact with the 
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GrA CPS:  a  Bacillus pumilis  species, strain  Shl 7, and Streptococcusfaecalis  (24- 
26). 
The structure of the GrA CPS has been shown (27) to be a  pseudo-randomly 
O-acetylated, a-1 ~  6-1inked linear homopolymer of manNAc-l-PO4. A  similar 
structure  has been  detected  in B.  pumilis  (26).  B.  pumilis  and  the  crossreacting 
strains  of S. fecalis  are  not  common  inhabitants  of the  human  flora  and  it  is 
unlikely that these bacteria are major stimuli for the widely prevalent GrA CPS 
antibodies. Two crossreactive B. pumilis strains, however, were detected in stool 
cultures of skid row inhabitants of the Pacific Northwest during an outbreak of 
GrA meningitis (28,  29). 
We  report  the  discovery of two Escherichia  coli  CPS  (K antigens),  K51  and 
K93, that are crossreactive with GrA CPS, and describe some of their epidemi- 
ological, biological, and immunologic properties.  The structure  of these two E. 
coli CPS will be reported elsewhere (Guirguis,  Bax, Egan, Schneerson,  Robbins, 
submitted for publication). 
Materials and  Methods 
Population.  The crossreacting E.  coli were discovered during a study of the etiology 
and  some laboratory characteristics of bacterial  meningitis  in  Egypt,  1977-1978  (30). 
Suspected meningitis cases, admitted on Tuesday of each week, were selected for a study 
of household contacts. A total of 96 families were examined. The families were visited in 
their homes and stool specimens were obtained from 645 members of these 96 families. 
Bacteria.  Crossreactive bacteria were identified by the antiserum agar technique (31). 
The 645 stool samples were streaked onto minimum essential medium (Difco Laboratories, 
Inc.,  Detroit,  MI) containing  3%  equine  GrA  meningococcal  serum  (H49)  and  1.2% 
agarose (Marine  Colloids,  Rockport,  ME).  Controls  included  antiserum agar prepared 
with equine group B and burro group C meningococcal antisera (6,  21).  The plates were 
incubated at 37°C for 24 h and at 4°C overnight and were then inspected for halos. The 
11 E. coli strains were the only bacterial species that yielded immunospecific halos on the 
H49 antiserum agar. 
E. coli strains, isolated from the urine (253 patients), tissues (3), wounds (35), and stools 
(29) of patients in the Clinical Center, National Institutes of Health (NIH), Bethesda, MD 
were kindly donated by Dr. Vee Gill. E. coli strains were isolated from 105  stool samples 
from school children in Copenhagen with diarrhea submitted to the Statens Seruminstitut. 
Five E. coli colonies, with different colonial morphology, from each stool specimen were 
plated onto H49 antiserum agar. 
Fermentation reactions and serotyping of crossreactive E. coli were done at the Collab- 
orative Center for Reference and  Research on Escherichia (WHO),  Copenhagen,  Den- 
mark,  by  established  methods  (32).  N.  meningitidis  group  X  (GrX)  strain  $2795  was 
donated by Dr. Harry Feldman, State University of New York, Upstate Medical Center, 
Syracuse, NY. 
Antisera.  Hyperimmune sera against GrA strain A1; E. coli K93 strains 999-78,  1064- 
78, and 1084-77; E. coli K51 strain 61-78; and B. pumilis Shl7 were produced by multiple 
intravenous injections of formalinized cells into a horse and into rabbits, as described (33). 
Three rabbits were injected with each strain. 
Polysaccharides.  GrA CPS, obtained from strain A1, was donated by Drs. Carl Frasch 
and Chou Ming Tsai, Office of Drugs and Biologics, FDA, Bethesda, MD. GrX CPS was 
kindly donated by Dr. Harold Jennings,  Medical Research Council, Ottawa, Canada. E. 
coli K93 and K51 and B. pumilis Sh 17 polysaccharides (PS) were prepared by transferring 
2.0 liters of a 6 h growth to a 50 liter fermenter containing minimum essential medium, 
supplemented with 0. ! % dialyzed yeast extract (21).  After 16 h incubation at 37°C with 
vigorous aeration,  the  culture  was centrifuged  and  an  equal  volume of 0.2%  (wt/vol) 
cetyltrimethylammonium bromide (Cetavalon;  Sigma Chemical  Co.,  St.  Louis,  MO)  in GUIRGUIS ET  AL.  1839 
water was added to the supernatant. The resulting precipitate was separated by centrifu- 
gation and thoroughly suspended in 0.9 M CaCI2.  The polysaccharides were purified by 
extraction with DNase, RNase, cold phenol, and ultracentrifugation as described (34-36), 
and contained <1% wt/wt of protein, nucleic acids, and lipopolysaccharide. Gel filtration 
of the  purified E.  coli CPS  used  CL-4B Sepharose  (Pharmacia,  Inc.,  Piscataway,  NJ) 
equilibrated in 0.2 M NaCI (35). The K93 CPS was de-O-acetylated by heating in 0.1  M 
ammonium hydroxide at 37°C for 1 h. 
Serology.  Double  immunodiffusion  and  rocket  immunoelectrophoresis  were  per- 
formed as described (22, 37,  38). Overnight cultures of the K93 and K51 strains were 
adjusted  to OD  1.4  at  540  nm.  The  CPS  concentrations of these supernatants  were 
compared with standard solutions of 5-300/*g/ml of either K93 or K51 CPS. The plates 
were dried, washed, and stained with 1% Coomassie Brilliant Blue. 
Quantitative precipitation analysis  was performed by adding 0.5 ml of 25-300/*g/ml 
polysaccharide solutions to 0.5 ml of antiserum. The tubes were mixed and then incubated 
at 37°C for  1 h and at 4°C  for 48 h, with occasional agitation. The precipitates were 
separated by centrifugation, washed three times with 0.15 M NaCI, and dissolved in 0.8% 
sodium dodecyl sulfate (SDS). Their protein content was measured by absorption at 280 
nm, assuming an antibody extinction coefficient of 14.0 (22). Hemophilus influenzae  type 
b (Hib) CPS was used as a control. 
Bactericidal Reactions.  The complement-dependent bactericidal assay was performed 
with GrA strain A1  organisms and E. coli K51 and K93 rabbit antisera before and after 
absorption with either GrA, K93, or K51 CPS (22, 39). Pre-colostral calf serum was used 
as the source of complement. Heat-inactivated H49 antiserum and fetal calf serum were 
used as controls. 
Antimicrobial  Sensitivity Tests.  The following antimicrobial disks  were used: penicillin 
(10 ug/disk), ampicillin (10 /*g/disk),  cephalothin (30 /*g/disk),  neomycin (30 /*g/disk), 
erythromycin (15/*g/disk), gentamycin (10/,g/disk), kanamycin (30/*g/disk), streptomycin 
(10/*g/disk), chloramphenicol (30/*g/disk), tetracycline (30/*g/disk), sulfisoxazole (0.25 
rag/disk),  and  tobramycin (10  /*g/disk).  Mueller-Hinton agar,  4  mm  deep,  was  used. 
Staphylococcus aureus  ATCC  25923, E.  coli 25923, and Pseudomonas  aeruginosa  ATCC 
27853 were obtained from the Centers for Disease Control (CDC), Atlanta, GA and used 
as reference strains. 
Toxin Production.  Enterotoxin production was examined by the Chinese hamster ovary 
cell assay for the detection of heat-labile, cholera-like enterotoxin (LT) and by the suckling 
mouse assay for the production of heat-stable enterotoxin (ST) as described (40, 41). 
Invasiveness.  The 11 crossreactive strains from Egypt were tested for invasiveness  in 
the guinea pig conjunctivitis model as described by Sereny (42).  Positive and negative E. 
coli strains for LT, ST, and invasiveness were kindly provided by Dr. R.  L. Geurrant, 
University of Virginia Medical School, Charlottesville, VA. 
Results 
Prevalence  and  Characterization  of  Escherichia  Coli  Crossreactive  with  GrA 
CPS.  Halo-positive  organisms,  cultivated  on  the  H49  antiserum  agar  plates, 
were  found in  11  of 645  (1.7%)  stool  specimens  obtained in  Egypt (Table I). 
These isolates gave fermentation reactions characteristic of E. coli;  10 of the  11 
strains showed an unusual marker that was adonitol positive and late or rhamnose 
negative. These  10 strains belonged to the sero-biotype 0107:K93:H27  or the 
flagellar, negative SP type, and may be considered to be progeny of a  single E. 
coli strain  or a  clone.  Eight of these  10 isolates gave spontaneous agglutination 
(SP) when tested against H  antisera. All K93 strains were crossreactive with K53 
antiserum; this serological reaction was shown to be due to their CPS (43). The 
remaining crossreactive E.  coli  strain  was typed as O7:K51:H 18 and lacked the 
adonitol  marker.  WHO  Reference E.  coli  strains  of K51  and  K93,  although 1840  E.  COLI  K51,  K93,  GROUP  A  MENINGOCOCCUS 
TABLE  I 
Identification,  Serotype Source, and Reactivity with Equine Group A Meningococcal 
Antiserum-agar of Bacteria 
Serotype 
Strain designation  Source 
0:  K:  H: 
Halos on GrA 
meningococcal 
(H49) antise- 
rum agar 
Survey No.  1. Egypt, 1977-1978 (n =  645) 
61-78  7  51  18 
163-78  107  93  27 
464-78  107  93  27 
999-78  107  93  SP. 
1014-78  107  93  SP.* 
1064-77  107  93  SP. 
1064-78  107  93  SP. 
1084-77  107  93  SP. 
1084-78  107  93  SP. 
1109-77  107  93  SP. 
1139-77  107  93  SP. 
Human stool 
Survey No. 2. Clinical Center, N1H,  1984 (n =  320) 
51-6-84  1  51  7  Human stool 
4-5-84  107  93  27  Human urine 
19-5-84  107  93  27  Human urine 
188-10-84  17  93  18  Human spleen 
314-12-84  17  93  18  Human sacrum wound 
Survey No. 3. School Children, Copenhagen, Denmark, 1985 (n =  105) 
F39950.85  17  93  18 
F39229.85  17  93  18 
F39830.85  17  93  18 
Human stool 
WHO Reference E. coli strains: 
A 183a  1  51  --  Human, appendicitis 
1935  150  93  6  Chicken, septicemia 
PA236  6  53  --*  Human, peritonitis 
B. pumilis (Sh 17) 
N. meningitidis GrA (A1) 
N. meningitidis GrX ($2795) ~ 
Human stool 
Human CSF  ~ 
Human CSF 
*  Spontaneous agglutination. 
:~ The E. coli K53 PS is crossreactive with K93. 
§ From the collection of Dr. Harry Feldman, SUNY, Syracuse, NY. 
II Cerebrospinal fluid. 
differing in  their O antigens,  gave strong halos on  H49  antiserum agar.  The 
WHO K53  test strain,  known  to crossreact with  K93, did not yield detectable 
halos with H49 antiserum agar (44). 
Four K93 strains and one K51  strain were found among 320 E.  coli samples 
(1.6%) from patients at the NIH Clinical Center. The serotypes of these strains GUIRGUIS ET AL.  1841 
were as follows: (a)  two from urine were O107:K93:H27;  (b) one from spleen 
taken during an autopsy was O 17:K93:H 18; (c) one from a wound infection was 
O77:K93:H18, and (d) one from stool was Ol:K51:H7. Three K93 strains were 
found among the  105  (2.9%)  stool samples from children in Copenhagen; all 
were of the O17:K93:H18  serotype; no K51  strains were found in this survey 
(Table I). 
Antibiotic Sensitivities.  The 11 crossreactive strains from Egypt varied in their 
susceptibility to antimicrobial drugs; most of them were sensitive to cephalothin, 
erythromycin, gentamycin, and  tobramycin  and  were  resistant  to  penicillin, 
ampicillin, neomycin, kanamycin, streptomycin, chloramphenicoi, tetracycline, 
and sulfisoxazole. 
Invasiveness  and  Enterotoxigenicity.  None  of the  crossreactive isolates  from 
Egypt were invasive in the guinea pig corneal test nor did they secret ST or LT. 
Rocket lmmunoelectrophoresis.  All  11  overnight culture supernatants of the E. 
coli K93 and K51 strains from Egypt exhibited rapid anoda| migration (data not 
shown). The intensity of the E.  coli CPS rockets was less than that of the GrA 
CPS. The rockets formed by the K93 and K51 CPS were higher but less intense 
than those formed by the GrA CPS at comparable concentrations. The amount 
of K93 CPS produced by the 10 strains varied between 12 and 25 #g/ml culture 
supernatant. 
Serological.  Fig.  1 shows halos of immunoprecipitation surrounding colonies 
of a representative strain ofE. coli K93 (999-78) on H49 agar. Similar halos were 
observed with GrA, GrX, and E.  coli  K51  organisms. No halos were observed 
with these or the other K51  or K93 strains grown on antiserum agar prepared 
with either group B or group C meningococcal antiserum or with H49 antiserum 
absorbed with GrA CPS. 
Fig. 2 shows double immunodiffusion of the supernatants of E.  coli K93 and 
K51 overnight cultures with H49 antiserum. All nine K93 strains exhibited an 
identical reaction with each other and a partial identity with GrA CPS. The K51 
FIGURE  I.  Halo  formation surrounding  colonies of Escherichia coli, strain 999-78, serotype 
O107:K93:SP, cultivated  on H49 equine GrA meningococcal  antiserum  agar. Halos, indistin- 
guishable from those formed by this organism, were formed by all E. coli K51 and K93 and 
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FIGURE 2.  Double immunodiffusion of the supernatants  from overnight cultures of E.  coli 
K93 and K51 strains with equine GrA meningococcal antiserum (H49). Wells 1 and 7 contain 
GrA meningococcal CPS,  100 ttg/ml. The following wells contained the supernatants from E. 
coli K93 strains: (2)  1139-77, (3)  1109-77, (4) 163-78, (5) 464-78, (6) 999-78, (8) 1014-78, (9) 
1064-78, (10) 1084-77, (11)  1084-78; (12) the supernatant from K51  61-78. All supernatants 
from E. coli K93 strains exhibited an identical reaction with each other and a partial identity 
with GrA CPS. The K51  supernatant in well 12 yielded a partial identity with both GrA CPS 
and K93 CPS. 
CPS  yielded a  partial  identity with both  K93  and GrA CPS.  Identical results 
were obtained with the purified K93 and K51 polysaccharide (data not shown). 
Fig.  3  shows the antigenic relations between the four PS and four antisera. 
The B. pumilis  Sh 17 PS yielded a nonidentical reaction with both K93 and K51 
CPS and a partial identity reaction with the GrA CPS when examined against 
the H49 antiserum (Fig. 3A). 
None of the rabbits immunized with the K93 strains, the K51 strain, or with 
the Sh 17 strain had preexisting precipitating antibodies, as measured by double 
immunodiffusion, to any of the four PS. The rabbits injected with the K93 and 
K51 strains responded in a similar fashion after the first course of immunization; 
all the sera showed homologous but not heterologous precipitating antibodies. 
In contrast, the antisera obtained from the rabbits  immunized with the Shl7 
strain showed both homologous and GrA CPS reactions after the first immuni- 
zation. The antisera taken after the second course of immunization with the K93 
and K51 strains precipitated with the homologous as well as with the GrA CPS. 
The  K93  antiserum  obtained  after  the  second  course  of immunization also 
precipitated with the K51 CPS. The hyperimmune K51 antisera, in contrast, did 
not react with the K93 CPS or Shl7 PS. 
After  the  second  immunization,  the  K93  sera  (Fig.  3B)  yielded  a  dense 
precipitin band with K93 CPS and a partial identity reaction with GrA CPS. Fig. 
3B fails to show the faint reaction between the K93 serum and the K51  CPS. 
No reaction was observed between K93 antiserum and the Shl 7 PS. 
Similarly, the K51  serum yielded (Fig.  3C)  a  dense precipitin line with the 
K51  CPS  and a  partial identity reaction with the GrA CPS.  No  reaction was 
observed between the K51 antiserum and the K93 CPS and Shl7 PS. GUIRGUIS  ET  AL.  1843 
FIGURE 3.  Double immunodiffusion  of hyperimmune antisera with purified PS. The center 
wells contain the following: (A) equine meningococcal GrA antiserum (H49), (B) rabbit E.  coil 
K93 antiserum, (C) rabbit E.  coli K51, (D) rabbit B.  pumilis Shl 7. Outer wells contained the 
following PS at 100 #g/ml: (1 and 4) meningococcal GrA CPS, (2) E.  coli K93 CPS, (3 and 5) 
B. pumilis Shl7 PS, (6) E.  coil K51 CPS. 
Fig. 3 D shows an identity reaction between the Sh 17 antiserum and the Shl 7 
PS and  GrA CPS.  No reaction  was observed between the Shl7  antiserum  and 
either the K93 and K51  CPS. 
De-O-acetylation  of the  K93  CPS  resulted  in  complete  loss  of its  reactivity 
with H49 antiserum and in a partial  identity reaction, compared with the native 
K93 CPS when reacted against  the rabbit K93 antiserum  (data not shown).  All 
K93 preparations gave an identical reaction with the WHO E. coli K53 reference 
serum (data not shown). 
Absorption  Experiments.  Fig.  4  shows the effect of absorption  with the  four 
polysaccharides upon the precipitating antibodies of the H49 antiserum.  Absorp- 
tion of H49 antiserum  with the GrA CPS removed its precipitin activity against 1844  E.  COLI  KS1,  K93,  GROUP  A  MENINGOCOCCUS 
FIGURE 4.  The effect of absorption- with  the  homologous and  crossreacting  PS  upon  the 
reactivity of  equine GrA meningococcal antiserum (H49). Central wells contained the following 
antisera. (A) H49 absorbed with GrA CPS. (B) H49 absorbed with E.  coil K51  CPS. (C) H49 
absorbed  withE,  coli  K93 CPS. (D) H49 absorbed with B. pumilis  Sh17  PS. Peripheral wells 
contained the following PS at  100 #g/ml: (1)  GrA CPS. (2) E.  coil K93 CPS, (3) E.  coil  K51 
CPS, (4) B. pumilis Sh 17 PS. 
all four polysaccharides (Fig.  4A). Absorption of H49 antiserum with the K51 
CPS removed only the homologous reaction; the absorbed serum still precipitated 
with K93  and Shl7  PS (Fig.  4B).  Absorption of H49 antiserum with the K93 
CPS removed its reaction with the K93 and the K51  CPS (Fig.  4 C).  The K93- 
absorbed  H49  antiserum  still  precipitated with  Shl7  PS.  Absorption  of H49 
antiserum with Shl7 removed only the Sbl7 PS reaction (Fig. 4, C-D). 
Quantitative Precipitation Analysis.  Fig.  5 shows that all four PS gave a  sym- 
metrical precipitation  curve, typical of a  single antigen,  with H49  antiserum. 
The H49  GrA antiserum  contained 5.1  mg GrA CPS antibody (Ab)/ml.  The 
K51,  K93,  and  Shl7  PS  precipitated  25,  46.8,  and  50%  of H49  antibodies, 
respectively. Hib CPS (control) did not precipitate with H49 antiserum. 5 0 rEquin e Group A Meningococcul 
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FIGURE 5.  Quantitative precipitation analyses of the reaction between GrA meningococcal 
E. coli K93 and K51, B. pumilis Shl7, and Hib PS and equine GrA meningococcal (H49), 
rabbit E. coli K93, and rabbit E. coli K51 antisera. PS (25-300/~g) in 0.5 ml were added to 
0.5 ml of each antisera, mixed, and incubated at 37°C for 1 h and at 4°C for 48 h, with 
occasional agitation. The precipitates were separated by centrifugation, washed with saline, 
dissolved in 0.8% SDS solution and their protein content measured by absorbance at 280 nm. 
1845 
K93 rabbit antiserum (strain 999-78), after the first immunization, had 4.1  mg 
K93 CPS Ab/ml; there was no detectable precipitate with the GrA, K51, or Sh 17 
PS. After the second immunization,  tbe K93 antiserum contained 4.6  mg K93 
CPS Ab/ml; GrA CPS precipitated 7% of these antibodies (Fig. 5). 
Similarly,  K51  rabbit  antiserum  had  4.5  mg  K51  CPS  Ab/ml  and  had  no 
precipitating GrA CPS antibodies after the first immunization. After the second 
immunization, however, there were 9.0 mg K51  CPS Ab/m|; GrA CPS precipi- 
tated  25%  of  these  antibodies.  Sbl7  antiserum  had  4.9  mg  Ab/ml  to  the 
homologous CPS antigens after the first immunization. Both GrA CPS and Shl 7 
PS precipitated  4.9  mg Ab/ml  from this antiserum  (data  not shown),  which is 
consistent with the immunodiffusion data (Fig. 3D). 
Bactericidal Activity of Escherichia Coli K93 and K51 Rabbit Antisera Against GrA 
Meningococci.  Preimmunization sera of the rabbits had low levels of bactericidal 
activity to GrA strain A1  (Table II). A  progressive increase in bactericidal titer 
was  observed with all  the sera  taken after the  first and  second immunizations 
with the K51 and K93 E.  coli. Absorption of both the K93 and K51 sera, taken 
after the second immunization, with GrA or with their homologous CPS reduced 
their titers to preimmunization  levels. Absorption of the  K93 serum  with  K51 
CPS  did  not  result  in  a  detectable  loss  of  bactericidal  activity  against  GrA 
organisms.  In  contrast,  absorption  of the  K51  antiserum  with  the  K93  CPS 
resulted in a fourfold reduction in bactericidal activity against the GrA strain. 
K93 and K51 CPS.  Gel filtration on Sepharose CL-4B showed a homogenous 
component of 0.30 Kd (partition coefficient) for the K93 CPS and 0.34 Kd for 
the  K51  CPS  (data  not  shown).  The  eluted  fractions  precipitated  with  H49 
antiserum by double immunodiffusion. 1846  E.  COLI K51,  K93,  GROUP  A  MENINGOCOCCUS 
TABLE  II 
Complement-dependent Bactericidal Activity against Group A Meningococcus Strain A1 of 
Rabbit Antisera  to Escherichia coli K93 and K51 Before and After Absorption with Group A 
Meningococcal and E. Coli K51 and K93 Capsular Polysaccharides 
Reciprocal bactericidal titers 
Rabbit sera  Absorbed with CPS 
Unabsorbed 
GrA  K93  K51 
K93 (999-78) 
Preimmunization  16  ND  ND  ND 
Post 1st immunization  512  ND  ND  ND 
Post 2nd immunization  4,096  8  32  4,096 
K51 (61-78) 
Preimmunization  4  ND  ND  ND 
Post 1st immunization  64  ND  ND  ND 
Post 2nd immunization  1,024  4  256  4 
ND, not determined. 
Discussion 
Serum  GrA  CPS  antibodies  have  been  demonstrated  in  most  children  and 
adult  humans  in  the  United  States  despite  the  rarity  of this  organism  in  this 
country during the past thirty years (1, 6,  18, 45-51). The development of GrA 
CPS "natural" antibodies is age related and has been reported to confer immunity 
to meningitis caused by this organism (1, 2, 6,  18). CPS antibodies can be elicited 
during convalescence from disease or from asymptomatic carriage of the homol- 
ogous organism  (6);  it  is  unlikely,  however,  that  this  is  the  only or the  major 
stimulus for the production of GrA CPS antibodies. The most probable antigenic 
source  for  GrA  CPS  antibodies  is  crossreactive  bacteria  from  gastrointestinal 
flora (10-26).  Despite their  structural  and serological similarities,  it is unlikely 
that  the B.  pumilis  Shl7  PS  is an  important  stimulus  for the  widely prevalent 
GrA CPS antibodies.  E.  coli strains  of the  K51  and  K93 capsular  types have a 
prevalence rate  of ~2%  in  surveys from  three  continents,  including  the  U.S., 
and could he a likely source of this antigenic stimulus. 
The K93 isolates from Egypt and the U.S. were of the O107:KO3:H27 serotype. 
The consistent pattern of serotype, antibiotic sensitivity, and metabolic properties 
among the  K93 strains  from Egypt is consistent with the  hypothesis that  these 
organisms are descendents of a single bacterium and may be considered a "clone" 
(44).  The  WHO reference E.  coli  K51  and  K93  strains  also showed this  cross 
reactivity with GrA CPS. The CPS purified from the WHO reference KO3 and 
K51  and  our  isolates  were  indistinguishable.  The  E.  coli  K53  CPS,  which  is 
crossreactive with KO3, did not react with H49 antiserum (43). 
E. coli K51, K53, and K93 are common capsular antigens found in association 
with several different O-antigens.  Both Vahlne (52) and Sjostedt (53) described 
common  serotypes  of E.  coli  with  K51  and  K53  CPS  isolated  from  human 
extraintestinal  disease and from normal feces. Strains with K51, K53, and  K93 
CPS were all represented  in E.  coli blood isolates from patients in the U.S. and 
Denmark  (54,  55).  It is likely that  some of the earlier described K53 strains  in GUIRGUIS  ET  AL.  1847 
these  studies were  actually K93  strains.  It  also  appears  from  the  files at  the 
Escherichia Centre in Copenhagen that these K CPS are represented not infre- 
quently in strains from both man and animals. K93 strains are found in isolates 
from the urinary tract. Strains with K51 and K93 antigens should, therefore, be 
regarded as belonging to that group of opportunistic pathogenic E.  coli that are 
commonly found in  the  human intestine and which may cause extraintestinal 
disease (59). Such strains are well suited to stimulate GrA CPS antibodies without 
causing disease in the healthy host.  K93 strains were more frequent than K51 
strains in our surveys and were more crossreactive with the GrA CPS than the 
K51  CPS.  It is likely, therefore, that the K93 is a more important stimulus for 
GrA CPS antibodies than either the K51 CPS or Shl7 PS. 
The absorption experiments with H49 antiserum and the K93, K51, or Sh 17 
PS showed the antigenic relations between these crossreactive antigens. GrA CPS 
absorbed both the homologous and crossreactive antibodies from H49 antiserum. 
Shl7 PS, reported to be composed of a linear homopolymer of--* 6)-manNAc- 
1-(PO4  ~  ,  glycerol phosphate  teichoic acid-containing N-acetylglucosamine, 
alkali-labile alanine esters, and a  mucopeptide, is closest of the three PS  in its 
structure to GrA CPS (26).  The crossreactivity of Shl7 PS with GrA CPS can 
be explained by its content ofpoly--* 6)-manNAc- 1-(PO4 ---~. Sh 17 PS precipitated 
50% ofGrA CPS antibodies when tested by the quantitative precipitation analysis. 
K51 was found to be a polymer of ~  3)-GlcNAc-1-(PO4 ---~. Yet, this apparently 
closely related structure was the least crossreactive of the three PS,  removing 
only  25%  of the  GrA  CPS  antibodies  from  the  H49  serum.  Although  N- 
acetylglucosamine and N-acetylmannosamine are epimers,  the linkages and 0- 
acetylation between the two CPS are different. 
The surprising finding was that K93 CPS, capable of precipitating 46.8%  of 
GrA CPS antibodies from H49 antiserum, had no obvious structural resemblance 
to GrA CPS.  K93 CPS is composed of an unusual disaccharide-repeating unit, 
galactofuranose and glucuronic acid, and contains no mannosamine or phosphate 
group. The unexpected crossreaction presumably derives from the three-dimen- 
sional similarity between the  K93  CPS and the GrA CPS,  a  point we plan to 
pursue.  The importance of the three-dimensional similarity in conferring this 
crossreactivity was shown by the change in reactivity between the de-0-acetylated 
and native K93 CPS with both the H49 and K93 antisera. A similar relationship, 
between the three-dimensional structure ofpyruvylated  derivatives of  D-galactose 
and D-glucose  and their reactivity with human monoclonal antibodies, has been 
reported (56). 
The immune rabbit sera elicited by intravenous injection of both E.  coti K93 
and K51 strains had bactericidal activity against GrA organisms. These E.  coli- 
induced bactericidal  antibodies were  removed by  absorption  with  GrA  CPS. 
Cross-absorption experiments showed that K93 CPS was capable of absorbing 
most of the bactericidal effect of K51 antiserum on GrA organisms; the reverse 
was not demonstrable. These findings suggest that K51  and K93 strains are an 
antigenic stimulus for the widely prevalent GrA CPS bactericidal antibodies and 
the immunity in areas with few or no GrA organisms. It is also possible that these 
crossreactive E.  coli strains in the gastrointestinal tract could stimulate blocking 
GrA CPS antibodies of the IgA isotype, as Griffis has suggested (57).  The use of 1848  E.  COLI K51, K93, GROUP  A  MENINGOCOCCUS 
the purified E.  coli  K51  and  K93 CPS as immunoadsorbents in human sera, as 
has  been done with  the  crossreacting E.  coli  K100  CPS  and  Hib CPS,  should 
provide further information on these possibilities (23, 58). 
Summary 
Eleven Escherichia  coli  strains,  crossreactive with  the capsular polysaccharide 
(CPS) of Neisseria meningitidis group A  (GrA), were detected among 645  stool 
isolates from healthy families in  Cairo,  Egypt.  I0  of these strains  were of the 
O107:K93:H27 or O107:K93:SP serotypes and may be considered descendents 
of a single bacterium or as a clone. The remaining crossreactive strain was of the 
O7:K51 :H 18 serotype. None of the  11  strains produced enterotoxins and none 
were  enteroinvasive.  The  purified  CPS  of  these  E.  coli  strains,  as  well  as  a 
polysaccharide (PS) from B. pumilis,  strain  Sh 17, precipitated with equine GrA 
(H49) antiserum.  A  partial identity between the E.  coli K93,  K51  and Shl7  PS 
on  the  one  hand  and  the  GrA  CPS  on  the  other  was  observed  by  double 
immunodiffusion when reacted against the H49 antiserum. Four K93 strains and 
one K51 strain were found among 320 E. coli strains from patients at the Clinical 
Center, National Institutes of Health, and three K93 strains were found in  105 
stool samples from children in Copenhagen.  The data from these three surveys 
suggest that these crossreactive E. coli are common organisms and could serve as 
a stimulus for "natural" GrA CPS antibodies. 
Quantitative precipitation analysis showed that K51,  K93, and Shl 7  PS pre- 
cipitated 25, 46.8, and 50% of H49 antibodies, respectively. Absorption of H49 
antiserum with the GrA CPS removed its precipitating activity with the E.  coli 
K93, K51, and Shl7 PS. Absorption of H49 antiserum with either K51  CPS or 
Shl7  PS  removed the  homologous crossreactivity only, whereas  K93  CPS  ab- 
sorbed both K93 and K51 reactivities. Antibodies, raised by intravenous injection 
of formalinized E. coli K93 or K51 cells into rabbits, precipitated with GrA CPS 
and were bactericidal against GrA meningococci. The crossreaction between the 
E. coli K93 and the GrA CPS was unexpected since these two CPS are composi- 
tionally so dissimilar. 
We are grateful for the review of this manuscript by Dr. Elvin A. Kabat. 
Received  for publication 28 May 1985. 
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